Advisors Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $548K | Buy |
21,645
+8,970
| +71% | +$197K | 0.01% | 968 |
|
|
2026
Q1 | $282K | Buy |
12,675
+3,906
| +45% | +$93.3K | ﹤0.01% | 1095 |
|
|
2025
Q4 | $234K | Sell |
8,769
-4,871
| -36% | -$116K | ﹤0.01% | 1102 |
|
|
2025
Q3 | $291K | Buy |
13,640
+173
| +1% | +$4.09K | ﹤0.01% | 1067 |
|
|
2025
Q2 | $290K | Sell |
13,467
-3,977
| -23% | -$73.9K | 0.01% | 1058 |
|
|
2025
Q1 | $290K | Sell |
17,444
-3,408
| -16% | -$61.9K | 0.01% | 1051 |
|
|
2024
Q4 | $383K | Sell |
20,852
-235
| -1% | -$3.79K | 0.01% | 984 |
|
|
2024
Q3 | $324K | Buy |
21,087
+2,499
| +13% | +$41.7K | 0.01% | 1021 |
|
|
2024
Q2 | $302K | Buy |
18,588
+4,332
| +30% | +$69.9K | 0.01% | 1026 |
|
|
2024
Q1 | $264K | Buy |
14,256
+6,019
| +73% | +$149K | 0.01% | 1079 |
|
|
2023
Q4 | $258K | Buy |
8,237
+244
| +3% | +$5.83K | 0.01% | 1075 |
|
|
2023
Q3 | $167K | Buy |
7,993
+5,982
| +297% | +$162K | ﹤0.01% | 1136 |
|
|
2023
Q2 | $48.2K | Buy |
+2,011
| New | +$44.7K | ﹤0.01% | 1287 |
|
|
2023
Q1 | – | Sell |
-1,892
| Closed | -$30.1K | – | 1449 |
|
|
2022
Q4 | $30.1K | Sell |
1,892
-22,046
| -92% | -$345K | ﹤0.01% | 1394 |
|
|
2022
Q3 | $392K | Sell |
23,938
-553
| -2% | -$8.96K | 0.01% | 985 |
|
|
2022
Q2 | $345K | Sell |
24,491
-3,706
| -13% | -$69.2K | 0.01% | 1041 |
|
|
2022
Q1 | $683K | Sell |
28,197
-1,862
| -6% | -$45.1K | 0.01% | 916 |
|
|
2021
Q4 | $702K | Sell |
30,059
-476
| -2% | -$9.57K | 0.01% | 913 |
|
|
2021
Q3 | $507K | Sell |
30,535
-232
| -0.8% | -$4.47K | 0.01% | 989 |
|
|
2021
Q2 | $750K | Buy |
30,767
+2,365
| +8% | +$53.4K | 0.01% | 911 |
|
|
2021
Q1 | $733K | Buy |
28,402
+13,414
| +89% | +$591K | 0.01% | 919 |
|
|
2020
Q4 | $801K | Buy |
14,988
+11,331
| +310% | +$562K | 0.01% | 837 |
|
|
2020
Q3 | $151K | Buy |
3,657
+1,694
| +86% | +$73.2K | ﹤0.01% | 1239 |
|
|
2020
Q2 | $95.1K | Buy |
+1,963
| New | +$94.2K | ﹤0.01% | 1311 |
|
|
2018
Q3 | – | Sell |
-9,897
| Closed | -$151K | – | 1575 |
|
|
2018
Q2 | $151K | Sell |
9,897
-1,621
| -14% | -$28.9K | ﹤0.01% | 1296 |
|
|
2018
Q1 | $287K | Sell |
11,518
-542
| -4% | -$15K | ﹤0.01% | 1175 |
|
|
2017
Q4 | $363K | Sell |
12,060
-1,198
| -9% | -$38.3K | 0.01% | 1135 |
|
|
2017
Q3 | $499K | Sell |
13,258
-1,351
| -9% | -$44K | 0.01% | 1059 |
|
|
2017
Q2 | $407K | Sell |
14,609
-579
| -4% | -$17.3K | 0.01% | 1148 |
|
|
2017
Q1 | $522K | Sell |
15,188
-824
| -5% | -$29.1K | 0.01% | 1084 |
|
|
2016
Q4 | $462K | Buy |
16,012
+6,866
| +75% | +$182K | 0.01% | 1145 |
|
|
2016
Q3 | $291K | Buy |
+9,146
| New | +$310K | ﹤0.01% | 1252 |
|
Other funds holding ACAD
BBA
RI
PAI
Advisors Asset Management's ACAD Position: Q2 2026 in Review
Advisors Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 71% in Q2 2026, buying an estimated $197K and bringing the position to 21,645 shares worth $548K. The position accounts for 0.01% of the portfolio, ranked #968.
Advisors Asset Management first reported a position in ACAD in Q3 2016 and has held it in 32 quarters since. The position peaked at $801K in Q4 2020. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.
- Advisors Asset Management held 21,645 shares of Acadia Pharmaceuticals worth $548K as of Q2 2026.
- Advisors Asset Management bought 8,970 Acadia Pharmaceuticals shares in Q2 2026, an estimated $197K.
- Acadia Pharmaceuticals made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #968 holding.
- Advisors Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2016 and has held it in 32 quarters since.
- Advisors Asset Management's Acadia Pharmaceuticals position peaked at $801K in Q4 2020.
- 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.
Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.